FTSE 100 inches higher as investors wait on Yellen
FTSE 100 added 8 to 6,825 and the FTSE AIM 0.4% to 792.5
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 47 of 55
Archive
Risers & fallers: Avanti Communications, San Leon Energy, Osirium Technologies, Bellzone Mining, Alexander Mining
Here we put the spotlight on Friday's market movers
UK shares close lower, wary of Fed speech, pharma dragged down by Clinton remarks
London shares closed lower on Thursday, nestled in negative territory throughout the session, as investors turned wary ahead of Fed chair Janet Yellen’s speech at Jackson Hole on Friday and pharma stocks were singed by Hillary Clinton’s pro
Mylan boss take the fight to Hillary
Mylan reacted by announcing plans to boost access to the product by expanding already-existing programs for patients who face what’s called out-of-pocket expenses.
Shire leads the fallers as £3.7bn is wiped from drugs sector after Clinton blast
Hilary Clinton took aim at one US drugs company - yet the shock waves were felt here in London.
AstraZeneca to sell antibiotics business to Pfizer
The deal is for its late-stage small molecule antibiotics business and involves three already-approved antibiotics - Merrem, Zinforo and Zavicefta - and two drugs in clinical trials (ATM-AVI and CXL).
Medivation faces buyers’ scrum - report
A scrum to acquire US cancer drug company Medivation was emerging on Wednesday after reports that Merck, Pfizer and Gilead Sciences were among at least five pharmaceutical companies expressing an interest
London stocks fall as oil prices hit six-week highs
London blue-chip stocks closed at their session nadir on Tuesday and their lowest since Thursday as a miners’ rally failed to buttress the main line ticker as oil prices hit six-week highs in Europe
FTSE 100 marks time despite buoyant mining sector
Blue-chips are becalmed after opening lower, though mining stocks continue to provide some cheer
FTSE 100 drifts lower despite demand for miners
The top seven Footsie performers are all miners, with Antofagasta topping the list after its half-year update
AstraZeneca combination fails final lung cancer trial, Array hit
Astra’s announcement was the second disappointing outcome for NSCLC sufferers in the space of a week.
Cantor sees much more upside for Sound Energy after Morocco breakthrough
Sound Energy shares have already climbed more than 250% since early July, but according Cantor's upgraded target there remains plenty of upside.
UK shares end softer as demand surges for gilts on rate cut talk
London's blue-chip stocks ended lower on Thursday after a session spent mostly suspended beneath the previous closing level as investors sought safer haven in UK government bonds, or gilts
Banking and oil woe drags FTSE 100 Index lower
The FTSE 100 Index was 6.56 points adrift at 6,743.87 in lunchtime trading
Generics hound AstraZeneca despite Brilinta star turn
New products saw an 8% sales rise to US$3.7bn with new heart disease drug Brilinta especially strong
Footsie treads water amid negative news from Lloyds
The FTSE 100 Index was 3.2 points adrift at 6,747.24 in early trading
PREVIEW: Investors look for signs of synergies from Shell's acquisition of BG
To misquote Prince, it’s just another frantic Thursday with around one-sixth of the FTSE 100 companies set to update the market.
Bid war beckons after Galenica snaps up Relypsa, brokers say
Brokers forecast rival interest after Galenica snaps up Relypsa for US$1.53bn